CDX-1401: Phase I/II started

Celldex began an open-label, U.S. Phase I/II trial to evaluate its IV varlilumab ( CDX-1127) and subcutaneous CDX-1401 in combination with Yervoy ipilimumab and the adjuvant poly-ICLC in about 100 p...